エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法について進行性子宮内膜がんを対象とした臨床第III相309試験/KEYNOTE-775試験の結果がthe New England Journal of Medicineに掲載 Eisai Jan 20, 2022 09:00 JST Read More
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Eisai Jan 20, 2022 08:56 HKT/SGT Read More
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time Eisai Jan 19, 2022 16:36 HKT/SGT Read More
エーザイ、DIAN-TUが実施する優性遺伝アルツハイマー病に対する抗MTBRタウ抗体E2814の臨床第II/III相試験に最初の被験者が登録 Eisai Jan 19, 2022 10:00 JST Read More
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study Eisai Jan 19, 2022 09:06 HKT/SGT Read More
아방스 클리니컬 바이오테크 쇼케이스 2022에서 미국에서의 확장을 위한 대규모적인 PE 투자를 발표 Avance Clinical Jan 19, 2022 07:00 HKT/SGT Read More
Tiny electric generators could accelerate wound healing Science and Technology of Advanced Materials Jan 18, 2022 22:00 HKT/SGT Read More
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 Avance Clinical Jan 18, 2022 13:00 HKT/SGT Read More
Senior Management Increases Shareholdings in EC Healthcare With Strong Confidence in the Group's Future Development EC Healthcare Jan 17, 2022 20:18 HKT/SGT Read More
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium Eisai Jan 17, 2022 10:44 HKT/SGT Read More
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health) Eisai Jan 13, 2022 12:26 HKT/SGT Read More
Arcensus has appointed Prof. Dr. Arndt Rolfs as New CEO Arcensus GmbH Jan 12, 2022 15:00 HKT/SGT Read More
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项 SinoMab BioScience Limited Jan 11, 2022 16:57 HKT/SGT Read More
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項 SinoMab BioScience Limited Jan 11, 2022 16:56 HKT/SGT Read More